Table 3.
Clinical characteristics in anti-PLA2R positive and negative patients with PMN.
| RC-IFA | ELISA | |||||
|---|---|---|---|---|---|---|
| Anti-PLA2R(+) | Anti-PLA2R(−) | P value | Anti-PLA2R(+) | Anti-PLA2R(−) | P value | |
| Age (years) | 45.77±15.65 | 50.48±16.88 | 0.209 | 46.55±15.76 | 48.90±16.95 | 0.526 |
| Gender (male%) | 27 (50.9%) | 15 (51.7%) | 0.946 | 27 (52.9%) | 15 (48.4%) | 0.689 |
| Proteinuria (g/day)* | 5.80±4.91 | 3.30±2.20 | 0.016a | 5.95±4.96 | 3.23±2.14 | 0.008b |
| Proteinuria >3.5 (g/day)d | 30 (60%) | 11 (40.7%) | 0.164 | 30 (62.5%) | 11 (37.9%) | 0.036c |
| Serum albumin (g/dL) | 27.50±25.65 | 26.89±8.89 | 0.904 | 27.23±26.15 | 27.37±8.70 | 0.977 |
| Blood urea nitrogen (mg/dL) | 6.48±5.07 | 6.39±2.94 | 0.929 | 6.56±5.15 | 6.27±2.91 | 0.773 |
| Serum creatine (umol/L) | 71.25±27.87 | 68.89±31.50 | 0.728 | 71.94±28.33 | 67.93±30.48 | 0.549 |
*
The data of proteinuria is absent in 5 cases.
a,b,c
Compared with anti-PLA2R negative group with RC-IFA or ELISA, P<0.05.
d
The data for this line was showed in form of number (%) of patients whose proteinuria was above 3.5 g/day.
P<0.05 is considered statistically significanti.